This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)

This study has been completed.
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA
Information provided by (Responsible Party):
University of Southern California Identifier:
First received: September 9, 2005
Last updated: May 20, 2014
Last verified: May 2014
This study is for patients with advanced cancer that has failed treatment with conventional therapy or for which no standard treatment exists. The purpose of this study is to determine the highest dose that can be given of 2 chemotherapy drugs, docetaxel (also called Taxotere) and liposomal doxorubicin (also called Doxil), when given together and to determine the side effects of this combination. Both Taxotere and Doxil are chemotherapy drugs that can decrease the size of several different tumors. Taxotere is approved by the Food and Drug Administration (FDA) for the treatment of breast and lung cancers, and Doxil is approved for the treatment of ovarian cancer.

Condition Intervention Phase
Cancer Carcinoma Drug: liposomal doxorubicin and docetaxel Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)

Resource links provided by NLM:

Further study details as provided by University of Southern California:

Primary Outcome Measures:
  • To determine the maximum tolerated dose (MTD) of liposomal doxorubicin (Doxil) administered every 4 weeks or every 2 weeks in combination with docetaxel (Taxotere) administered on a weekly schedule
  • To establish the toxicity profile of this combination

Estimated Enrollment: 35
Study Start Date: December 2000
Study Completion Date: May 2006
Primary Completion Date: October 2005 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histological proof of advanced or recurrent solid tumor which has failed prior therapy, or for which no effective therapy is available.
  • Ovarian cancer patients (or primary peritoneal carcinoma) whose only manifestation of disease is an elevated cancer antigen (CA) 125 of > 100 are eligible.
  • SWOG performance status 0-2.
  • Absolute granulocyte count (AGC) greater than or equal to 1.5; platelets greater than or equal to 100,000.
  • Total bilirubin less than or equal to the upper limit of normal (ULN).
  • Transaminases (SGOT and/or SGPT) may be up to 2.5 x institutional upper limit of normal (ULN) if alkaline phosphatase is <= ULN, or alkaline phosphatase may be up to 4 x ULN if transaminases are <= ULN. However, patients who have both transaminase elevation > 1.5 x ULN and alkaline phosphatase > 2.5 x ULN are not eligible for this study (due to decreased clearance of docetaxel and increased risk of toxicity).
  • Age greater than or equal to 18 years.
  • Fully recovered from acute toxicities from chemotherapy, radiation, or surgery.
  • Negative serum pregnancy test, if patient is female, still fertile, and sexually active.

Exclusion Criteria:

  • Prior treatment with Doxil or weekly docetaxel. Prior docetaxel administered every 3 weeks is allowed.
  • Evidence of moderate peripheral neuropathy greater than or equal to grade 2.
  • Medical, social, or psychological factors interfering with compliance.
  • Known history of cardiac disease (congestive heart failure, coronary artery disease) that would preclude treatment with Doxil in the opinion of the investigator.
  • Cardiac ejection fraction < 50%
  • Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00183742

United States, California
U.S.C./Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033
Sponsors and Collaborators
University of Southern California
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA
Principal Investigator: Syma Iqbal, M.D. U.S.C./Norris Comprehensive Cancer Center
  More Information

Responsible Party: University of Southern California Identifier: NCT00183742     History of Changes
Other Study ID Numbers: 0C-00-6
Study First Received: September 9, 2005
Last Updated: May 20, 2014

Keywords provided by University of Southern California:
Phase 1
Phase I
Phase one
Solid tumor

Additional relevant MeSH terms:
Liposomal doxorubicin
Antibiotics, Antineoplastic
Antineoplastic Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators processed this record on June 23, 2017